Ann Daly

Professor

Newcastle University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Ann Daly is a faculty member at Newcastle University in the United Kingdom. Her research primarily focuses on pharmacogenomics, drug-induced liver injury, and metabolic dysfunction-associated liver diseases. She has published recent articles exploring genetic factors influencing liver conditions and pharmacogenomic education in healthcare settings. Professor Daly contributes significantly to advancing knowledge in her field through her extensive research and publications.

Articles (30)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (30)

Einar Stefán Björnsson

ICELAND

Ann Daly

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Pharmacogenomics in 2023: Big studies, big results, big implications, big responsibilities: Editorial

Genetic and Genomic Approaches to the Study of Drug‐Induced Liver Injury

Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA—Update with genetic correlations

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

PharmVar GeneFocus: CYP4F2

Analysis of the current situation of pharmacogenomics in terms of educational and healthcare needs in Egypt and Lebanon

A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry

Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis

Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment

Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population

Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort

Relevance of Pharmacogenomics to the Safe Use of Antimicrobials

Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>☆</sup>” [J Hepatol (2020) 505–515, (S0168827820302130), (10.1016/j.jhep.2020.04.003)]

Genetics of drug-induced liver injury: Current knowledge and future prospects

Impact of Genetic Variations on Thromboembolic Risk in Saudis with Sickle Cell Disease

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Pharmacogenomics in practice: a review and implementation guide

Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.

A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers

Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.

PharmVar GeneFocus: CYP2C9.

Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.

Pharmacogenomics spotlight commentary: From the United Kingdom to global populations.

NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.

Collaborators (30)

Einar Stefán Björnsson

Jane Grove

Marta Afonso

Heather Cordell

Ingolf Cascorbi

Cristina Rodriguez-Antona

Aimo Kannt

Fiona Oakley

Jan-Philipp Mallm

Olivier Govaere

A.G. (Onno) Holleboom

Ann Driessen

Quentin M. Anstee

Marijana Vujkovic

Benjamin F. Voight

Romain Moirand

Kate Townsend Creasy

Dipender Gill

Carolin Victoria Schneider

Raúl J. Andrade

Scott DuVall

Steven Masson

Marwan Ghabril

Evangelia Eirini Tsermpini

Tiebing Liang

Matej Oresic

Rosellina Margherita Mancina

Felix Meissner

Simon Cockell

Robert J. Fontana

Make your next move.